A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway and its downstream effectors, Akt and mechanistic target of rapamycin (mTOR), is aberrantly activated in acute myeloid leukemia (AML) patients, where it contributes to leukemic cell proliferation, survival, and drug-resistance. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiarini, Francesca, Lonetti, Annalisa, Teti, Gabriella, Orsini, Ester, Bressanin, Daniela, Cappellini, Alessandra, Ricci, Francesca, Tazzari, Pier Luigi, Ognibene, Andrea, Falconi, Mirella, Pagliaro, Pasqualepaolo, Iacobucci, Ilaria, Martinelli, Giovanni, Amadori, Sergio, McCubrey, James A., Martelli, Alberto M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2012
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681499/
https://www.ncbi.nlm.nih.gov/pubmed/23271044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681499/
https://www.ncbi.nlm.nih.gov/pubmed/23271044

Ejemplares similares